CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Impact of cryopreservation on CAR T production and clinical response.
Impact of cryopreservation on CAR T production and clinical response.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过继性细胞治疗中的嵌合抗原受体(CAR)T细胞已成为血液系统恶性肿瘤患者的有效治疗选择。FDA批准的CAR-T 产品在集中式设施中由新鲜或冷冻的白细胞单采物制备,冷冻保存的CAR-T 输注产品被运送回患者。越来越多的临床中心在本地生产CAR-T 细胞,这使得可以使用新鲜和冷冻保存的PBMCs和CAR-T 细胞。
在此,我们在118例接受新鲜CAR-T 细胞治疗的患者队列中,以及在数例患者中进行头对头比较,确定了冷冻保存对PBMCs和CD19 CAR-T 细胞的影响。从白细胞单采产品中获得冷冻保存的PBMCs,其红细胞和T细胞较少,但足以生产用于治疗的CAR-T 细胞。PBMCs的回收率与转导效率、生产过程结束时获得的CAR-T 细胞数量、体外反应性或对CAR-T 治疗的缓解率之间没有相关性。
我们能够证明,在生产过程中冷冻保存、储存并在较晚时间点恢复扩增的CAR-T 细胞,可产生足够的细胞数量用于治疗,并导致完全缓解。包括T细胞亚型、趋化因子受体和共抑制/共刺激分子在内的表型分析显示,与冷冻对应物相比,新鲜CAR-T 细胞显著表达更多TIM-3,并含有较少的效应T细胞。
此外,新鲜CAR-T 输注产品表现出增强的体外抗肿瘤反应性,然而冷冻保存的CAR-T 细胞仍显示出高抗肿瘤效力和特异性。冷冻保存的CAR-T 细胞的回收率在缓解和未缓解患者中相似。尽管新鲜CAR-T 输注产物表现出更高的抗肿瘤反应性,但使用冻存PBMCs作为起始材料和冻存CAR-T 输注产物似乎是可行的选择,因为冻存产物仍表现出高的体外效力,且冷冻保存似乎不影响临床结局。
Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has become an efficient treatment option for patients with hematological malignancies. FDA approved CAR T products are manufactured in centralized facilities from fresh or frozen leukapheresis and the cryopreserved CAR T infusion product is shipped back to the patient. An increasing number of clinical centers produce CAR T cells on-site, which enables the use of fresh and cryopreserved PBMCs and CAR T cells.
Here we determined the effect of cryopreservation on PBMCs and CD19 CAR T cells in a cohort of 118 patients treated with fresh CAR T cells and in several patients head-to-head. Cryopreserved PBMCs, obtained from leukapheresis products, contained less erythrocytes and T cells, but were sufficient to produce CAR T cells for therapy. There was no correlation between the recovery of PBMCs and the transduction efficacy, the number of CAR T cells obtained by the end of the manufacturing process, the in vitro reactivity, or the response rate to CAR T therapy.
We could show that CAR T cells cryopreserved during the manufacturing process, stored and resumed expansion at a later time point, yielded sufficient cell numbers for treatment and led to complete remissions. Phenotype analysis including T cell subtypes, chemokine receptor and co-inhibitory/stimulatory molecules, revealed that fresh CAR T cells expressed significantly more TIM-3 and contained less effector T cells in comparison to their frozen counterparts.
In addition, fresh CAR T infusion products demonstrated increased in vitro anti-tumor reactivity, however cryopreserved CAR T cells still showed high anti-tumor potency and specificity. The recovery of cryopreserved CAR T cells was similar in responding and non-responding patients.
Although fresh CAR T infusion products exhibit higher anti-tumor reactivity, the use of frozen PBMCs as staring material and frozen CAR T infusion products seems a viable option, as frozen products still exhibit high in vitro potency and cryopreservation did not seem to affect the clinical outcome.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。